Ocuphire Pharma Investor Day Presentation Deck
9
OCUPHIRE
PHARMA
NASDAQ: OCUP
A Look Ahead Into 2022:
Nyxol MIRA-3 P3 trial for RM EARLY 2022
Nyxol Pediatric trial for RM EARLY 2022
Nyxol LYNX-1 P3 trial for NVD EARLY 2022
APX3330 ZETA-1 P2b trial for DR/DME 2H22
NDA Filing for Nyxol for RM LATE 2022
RM =
Reversal of Mydriasis
NVD = Night Vision Disturbances
DR/DME = Diabetic Retinopathy/Diabetic Macular Edema
▪ Differentiated, Late-Stage Pipeline for Front and Back of the Eye
✓ Nyxol with > 330 patients treated across 9 trials (505(b)(2) regulatory pathway)
✓ APX3330 with > 340 patients treated across 11 trials (NCE development pathway)
Nyxol and APX3330 achieved promising clinical data and favorable safety profile
across multiple Phase 1, 2, and 3 trials
✓
●
●
Poised for Commercial Success in Multiple Large Unmet Markets
✓ Addressing 4 large markets with unmet needs: RM, Presbyopia, NVD, and DR/DME
✓ Successful trial execution with 2 recent positive Phase 3 and Phase 2 data read-outs
for Nyxol in RM and Nyxol + LDP Presbyopia, respectively
✓ Stable, small-molecule drugs with commercial scalability
✓ Robust and growing IP portfolio: US and global issued thru 2034 for both assets as
well as new 2039 Nyxol patent issued for presbyopia
Many Catalysts in 2022 with Track Record of Execution
✓ $24.5 million cash reported at 12-31-21 sufficient for operations into 2Q 2023
✓ Highly experienced management, Board and KOLs with broad ophthalmic and
biotech drug development and commercialization success
✓ Lower-cost, fast-enrolling, shorter-duration clinical trials
✓ Favorable, precedent regulatory environment for ophthalmic drug approval
✓ Analyst coverage by Cantor, Canaccord, Jones Trading, Alliance Global, and HCWView entire presentation